Treatment with disease-modifying therapies (DMTs) should be initiated within 6 months of the onset of MS in order to minimize the long-term accumulation of disability, according to an analysis based on real-world data.
At ECTRIMS, Dr Pietro Iaffaldano from the University of Bari Aldo Moro, in Bari, Italy, presented details of the study. The aim was to evaluate the impact of the time interval from disease onset to the first administration of a DMT on long-term disability accumulation.
A cohort of 11,934 RRMS patients was identified using the Big Multiple Sclerosis Data Network – a collection of real-world data obtained from registries in Denmark, France, Italy, and Sweden, and from the international MSBase database.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.